Treatment of Parkinson's disease should begin with a dopamine agonist (Q33737392)

29 July 2017

1 reference

title

Treatment of Parkinson's disease should begin with a dopamine agonist (English)

1 reference

29 July 2017

0 references

1 reference

0 references

J L Montastruc

1

1 reference

29 July 2017

O Rascol

series ordinal

2

1 reference

29 July 2017

J M Senard

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

14

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

725-730

1 reference

New directions in the drug treatment of Parkinson's disease

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Long-term treatment of Parkinson's disease with bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Current status of dopamine agonists in Parkinson's disease management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Should treatment of Parkinson's disease be started with a dopamine agonist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Levodopa: is toxicity a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Lisuride, a dopamine agonist in the treatment of early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Early combination therapy with bromocriptine and levodopa in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Early dopaminergic drug-induced hallucinations in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

Cost effectiveness of pramipexole in Parkinson's disease in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199909%2914%3A5%3C725%3A%3AAID-MDS1003%3E3.0.CO%3B2-L

10.1002/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference